CYP2C9 amino acid residues influencing phenytoin turnover and metabolite regio- and stereochemistry

Journal of Pharmacology and Experimental Therapeutics

Volumn 329, Issue 3, 2009, Pages 938-944

  Mosher, Carrie M ^a   Tai, Guoying ^a   Rettie, Allan E ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 (4 HYDROXYPHENYL) 5 PHENYLHYDANTOIN; CYTOCHROME P450 2C9; FLURBIPROFEN; PHENYTOIN; WARFARIN;

ARTICLE; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVE SITE; LIGAND BINDING; PRIORITY JOURNAL; STEADY STATE; STEREOCHEMISTRY;

AMINO ACID SUBSTITUTION; AMINO ACIDS; ARYL HYDROCARBON HYDROXYLASES; BIOCATALYSIS; CATALYTIC DOMAIN; HUMANS; KINETICS; MODELS, MOLECULAR; PHENYTOIN; RECOMBINANT FUSION PROTEINS; STEREOISOMERISM; TANDEM MASS SPECTROMETRY; WARFARIN;

EID: 66749089988     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.109.150706     Document Type: Article

References (26)

1. Argikar UA, Cloyd JC, Birnbaum AK, Leppik IE, Conway J, Kshirsagar S, Oetting WS, Klein EC, and Remmel RP (2006) Paradoxical urinary phenytoin metabolite (S)/(R) ratios in CYP2C19*1/*2 patients. Epilepsy Res 71:54-63. (Pubitemid 44233199)
2. Bajpai M, Roskos LK, Shen DD, and Levy RH (1996) Roles of cytochrome P4502C9 and cytochrome P4502C19 in the stereoselective metabolism of phenytoin to its major metabolite. Drug Metab Dispos 24:1401-1403. (Pubitemid 26427180)
3. Bush ED, Low LK, and Trager WF (1983) A sensitive and specific stable isotope assay for warfarin and its metabolites. Biomed Mass Spectrom 10:395-398.
4. Cheesman MJ, Baer BR, Zheng YM, Gillam EM, and Rettie AE (2003) Rabbit CYP4B1 engineered for high-level expression in Escherichia coli: ligand stabilization and processing of the N-terminus and heme prosthetic group. Arch Biochem Biophys 416:17-24. (Pubitemid 36818845)
5. Dickmann LJ, Locuson CW, Jones JP, and Rettie AE (2004) Differential roles of Arg97, Asp293, and Arg108 in enzyme stability and substrate specificity of CYP2C9. Mol Pharmacol 65:842-850. (Pubitemid 38420489)
6. Giancarlo GM, Venkatakrishnan K, Granda BW, von Moltke LL, and Greenblatt DJ (2001) Relative contributions of CYP2C9 and 2C19 to phenytoin 4-hydroxylation in vitro: Inhibition by sulfaphenazole, omeprazole, and ticlopidine. Eur J Clin Pharmacol 57:31-36. (Pubitemid 32391409)
7. Gotoh O (1992) Substrate recognition sites in cytochrome P450 family 2 (CYP2) proteins inferred from comparative analyses of amino acid and coding nucleotide sequences. J Biol Chem 267:83-90.
8. Haining RL, Jones JP, Henne KR, Fisher MB, Koop DR, Trager WF, and Rettie AE (1999) Enzymatic determinants of the substrate specificity of CYP2C9: role of B'-C loop residues in providing the -stacking anchor site for warfarin binding. Biochemistry 38:3285-3292. (Pubitemid 129501388)
9. Leung AY, Chow HC, Kwong YL, Lie AK, Fung AT, Chow WH, Yip AS, and Liang R (2001) Genetic polymorphism in exon 4 of cytochrome P450 CYP2C9 may be associated with warfarin sensitivity in Chinese patients. Blood 98:2584-2587.
10. Liu KH, Kim MJ, Jung WM, Kang W, Cha IJ, and Shin JG (2005) Lansoprazole enantiomer activates human liver microsomal CYP2C9 catalytic activity in a stereospecific and substrate-specific manner. Drug Metab Dispos 33:209-213. (Pubitemid 40216587)
11. Mather GG and Levy RH (2000) Anticonvulsants, in Metabolic Drug Interactions (Levy RH, Thummel KE, Trager WF, Hansten PD, and Eichelbaum M eds) pp 217-232, Lippincott Williams & Wilkins, Philadelphia, PA.
12. Melet A, Assrir N, Jean P, Pilar Lopez-Garcia M, Marques-Soares C, Jaouen M, Dansette PM, Sari MA, and Mansuy D (2003) Substrate selectivity of human cytochrome P450 2C9: Importance of residues 476, 365, and 114 in recognition of diclofenac and sulfaphenazole and in mechanism-based inactivation by tienilic acid. Arch Biochem Biophys 409:80-91. (Pubitemid 36042904)
13. Merritt HH and Putnam TJ (1938) Sodium diphenyl hydantoinate in the treatment of convulsive disorders. JAMA 111:1062-1067. (Pubitemid 14190701)
14. Mosher CM, Hummel MA, Tracy TS, and Rettie AE (2008) Functional analysis of phenylalanine residues in the active site of CYP2C9. Biochemistry 47:11725-11734.
15. Negishi M, Uno T, Darden TA, Sueyoshi T, and Pedersen LG (1996) Structural flexibility and functional versatility of mammalian P450 enzymes. FASEB J 10:683-689. (Pubitemid 26172814)
16. Rettie AE, Haining RL, Bajpai M, and Levy RH (1999) A common genetic basis for idiosyncratic toxicity of warfarin and phenytoin. Epilepsy Res 35:253-255. (Pubitemid 29298118)
17. Rettie AE, Korzekwa KR, Kunze KL, Lawrence RF, Eddy AC, Aoyama T, Gelboin HV, Gonzalez FJ, and Trager WF (1992) Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: A role for P-4502C9 in the etiology of (S)-warfarin-drug interactions. Chem Res Toxicol 5:54-59.
18. Rettie AE, Tai G, Veenstra DL, Farin FM, Srinouanprachan S, Lin YS, Thummel KE, and Hines RN (2003) CYP2C9 exon 4 mutations and warfarin dose phenotype in Asians. Blood 101:2896-2897. (Pubitemid 36857661)
19. Rudis MI, Touchette DR, Swadron SP, Chiu AP, and Orlinsky M (2004) Cost-effectiveness of oral phenytoin, intravenous phenytoin, and intravenous fosphenytoin in the emergency department. Ann Emerg Med 43:386-397. (Pubitemid 38282651)
20. Takanashi K, Tainaka H, Kobayashi K, Yasumori T, Hosakawa M, and Chiba K (2000) CYP2C9 Ile359 and Leu359 variants: enzyme kinetic study with seven substrates. Pharmacogenetics 10:95-104.
21. Tracy TS, Hutzler JM, Haining RL, Rettie AE, Hummel MA, and Dickmann LJ (2002) Polymorphic variants (CYP2C9*3 and CYP2C9*5) and the F114L active site mutation of CYP2C9: Effect on atypical kinetic metabolism profiles. Drug Metab Dispos 30:385-390. (Pubitemid 34263822)
22. Uno T, Mitchell E, Aida K, Lambert MH, Darden TA, Pedersen LG, and Negishi M (1997) Reciprocal size-effect relationship of the key residues in determining regio-and stereospecificities of dhea hydroxylase activity in P450 2A5. Biochemistry 36:3193-3198. (Pubitemid 27142391)
23. Veronese ME, Doecke CJ, Mackenzie PI, McManus ME, Miners JO, Rees DL, Gasser R, Meyer UA, and Birkett DJ (1993) Site-directed mutation studies of human liver cytochrome P-450 isoenzymes in the CYP2C subfamily. Biochem J 289:533-538. (Pubitemid 23042065)
24. Wester MR, Yano JK, Schoch GA, Yang C, Griffin KJ, Stout CD, and Johnson EF (2004) The structure of human cytochrome P450 2C9 complexed with flurbiprofen at 2.0-Å resolution. J Biol Chem 279:35630-35637. (Pubitemid 39100565)
25. Williams PA, Cosme J, Ward A, Angove HC, Matak Vinkoviæ D, and Jhoti H (2003) Crystal structure of human cytochrome P450 2C9 with bound warfarin. Nature 424:464-468. (Pubitemid 36917499)
26. Zarza J, Hermida J, Montes R, Alberca I, López ML, and Rocha E (2002) Leu208Val and Ile181Leu variants of cytochrome P450 CYP2C9 are not related to the acenocoumarol dose requirement in a Spanish population. Blood 100:734. (Pubitemid 34761151)